Obesity
Conditions
Brief summary
12 obese subjects will receive peripheral administration of placebo and 4 escalating doses of PYY1-36 and another 12 obese subjects will receive peripheral administration of placebo and 4 escalating doses PYY3-36 on 5 different test days within one week. The patients will be tested in a single blinded dose escalating protocol. Measurements of appetite, ad libitum energy intake, blood pressure and blood sampling will be performed during the test day.
Interventions
DRUGperipheral Peptide YY administration
Sponsors
Aditech Pharma AB
University of Copenhagen
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE
Eligibility
Sex/Gender
MALE
Age
20 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Normal weight (BMI: 18-23 kg/m2) or 12 overweight/obese (BMI: 27-40 kg/m2) * Body weight fluctuations \< 5 kg over the past 2 months. * Blood pressure normal to mildly hypertensive(\<159/99 mm Hg) * Non-elite athletes and not planning to change physical activity during the study.
Exclusion criteria
* Any physiological or psychological illnesses that could influence the study results. * Regular use of medicine. * Smoking defined as \<1 cigarette per day. * Substance abuse or dependence. * Blood donation within the past 3 months before entering the study. * Drinking \>21 alcoholic units/week. * Food allergies. * Special diets (e.g. vegetarian) or dislikes to any of the foods served during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| appetite | — |
| energy intake | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma PYY profile | — |
| Blood pressure | — |
Outcome results
None listed